Table 2.

Antitumor effects of taccalonolides A, E, and N in the Mammary 16/C model.

Treatment	Total dose (mg/kg)	T/C (%)	T-C (days)	Gross log cell kill	Median (range) of tumor size and number of tumor- free mice on day 12	Mean body weight loss (%)
No treatment	-	-	-	-	1029 (63–2827)	−2.2
Paclitaxel	73.5	0	19	4.8	0 (all zero)	−6.3
Taccalonolide A	56	0	16	4.0	0 (all zero)	−16.7*
Taccalonolide A	40	24	4	1.0	256 (108–756)	−6.3
Taccalonolide E	90	17	5	1.25	172 (0–947) 1/5 = 0	−4.1
Taccalonolide E	54	81	1	0.25	837 (0–1755) 1/5 = 0	−2.0
Taccalonolide N	36	0	5	1.25	(0–126) 3/5 = 0	−8.2
Taccalonolide N	20	43	1	0.25	445 (0–2277) 1/5 = 0	−2.1

T/C is the median tumor mass of a given treated group (T) divided by the median tumor mass of the control (C) and expressed as a percent. The tumor growth delay (T-C) is the median number of days between the time the treatment (T) and control (C) group tumors reach the pre-determined size of 1000 mg. The gross log cell kill is calculated by (T-C)/3.32 × (Td), where Td is the tumor volume doubling time (in days).

^*A 20% lethality (1/5 mice) was observed at this dose.